JBK Associates International, Inc. is an award-winning, executive talent solutions organization specializing in the acquisition, management, and development of senior-level talent across a wide spectrum of functional responsibilities and industries. Founded in 2003 by Julie Kampf, the vision for the company since its inception has been to create a full-service talent solutions firm with a distinct differentiation. As a “boutique”, JBK prides itself on its “high touch/high return” philosophy and values. Our client relationships are truly partnerships, where we strive to be a trusted advisor and extension of our client team, thereby understanding the intricacies and culture of each and every one of our clients. At JBK Associates, the successful execution of a search assignment is the collaborative effort of the entire JBK team- we believe in everyone taking ownership of the quality of an outcome when a client engages JBK Associates as their search partner, they are on the receiving end of a collective experience base of more than 50 years. The firm has an unparalleled commitment to diversity and inclusion across all touch points of an assignment which is substantiated by metrics and further evidenced by our own work environment. We understand that excellence comes from all perspectives, so we treat diversity as a necessity, not a nice to have.

Aspira Women’s Health Inc. is transforming gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer.    

Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite^SM, which includes OvaWatch^SM, a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus^® combines our FDA-cleared products, Ova1^®and Overa^®, to detect risk of ovarian malignancy in women with adnexal masses planned for surgery.    

EndoCheck^SM, Aspira’s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at www.aspirawh.com.   

Wyant Simboli is a corporate story/branding partner focused on working closely with biopharma founders and CEOs to help define their company story, structure the aligned brand, and inspire their audiences. For more than 30 years, we’ve succeeded in helping our clients grow by building robust and extensible brand communications systems designed to meet current and future opportunities.

Luna Bioscience, Inc. is an R&D company developing solutions to globally-important infectious diseases with enormous unmet needs, in the form of vaccines, diagnostics, and therapeutics for livestock, companion animals and humans. We have proof-of-principle in two animal models for a novel vaccine candidate against leptospirosis, and are working on solutions to additional infectious diseases. Our novel genomics-based technology comes out of the Vinetz lab at Yale.

Research Activity:

Finding and developing solutions to globally-important infectious diseases with enormous unmet needs.

HAVEN is a leadership development firm that partners with high-growth biotech companies to provide leadership development. HAVEN ignites exceptional performance and cultivates capabilities in leaders and teams through Leadership Development training, Executive Coaching, and Team Coaching. HAVEN’s innovative training programs are especially designed for rapidly scaling companies that want to help their managers develop leadership skills required to engage people and teams to achieve their best. HAVEN works with clients to design custom programs to address their specific goals and align with the organizational culture. HAVEN executive coaches work with leaders 1:1 to explore their leadership opportunities, to deepen understanding and create lasting behavior change. HAVEN team coaching helps leadership teams diagnose their challenges and implement solutions to perform at their best.

Our mission is to enable and finance the development of life-saving genetic medicines for rare and ultra-rare patient populations previously deemed too rare to treat. To realize this, our unique ecosystem facilitates collaboration between world-renowned researchers and clinicians, policy experts and our generous donors. Together, we are fundamentally changing the rare and ultra-rare disease experience and burden for millions of people around the world with our discoveries and methods—while bringing hope to patients waiting for a cure.

Research Activities: Advanced modalities drug development for rare and ultra-rare neuromuscular and neurodegenerative diseases.

Intensity Therapeutics is a clinical-stage biotechnology company whose mission is to help patients live longer, higher quality lives by discovering, developing, and commercializing first-in-class cancer drugs that attenuate tumors with minimal side effects, while igniting the patient’s immune system to fight the cancer. Our lead product candidate, INT230-6, has been tested in ~200 patients in human clinical studies to treat refractory solid cancers.

Background and Key Achievements

We have late-stage pipeline programs in metastatic and presurgical settings with multiple near-term inflexion points. We have a robust IP portfolio, a platform validated through multiple Industry, government and university hospital partnerships, positive data that led to partnerships with Merck, Bristol Myers Squibb, and the National Institute of Health.  Recently we completed an oversubscribed, top-of-range initial public offering on the NASDAQ exchange, raising ~$22.5 million. The ticker is INTS.

Curie.Bio is a new model for venture capital in biotech focused on helping founders launch serious biotech therapeutics companies. Founded by Alexis Borisy, Christoph Lengauer, and Zach Weinberg, Curie.Bio is a unique combination of two businesses: they act as both your drug discovery co-pilot & seed investor. They have some of the world’s best drug hunters, drug makers, experts, and vendors supporting founders to increase their chances of developing successful medicines. They help founders avoid mistakes and ensure they have the right data, plan, and story to retain ownership and control over their own company. By doing this, Curie.Bio is enabling more founders with phenomenal ideas to have the support they need to start their own companies. Check out our recent press coverage from STAT, Fast Company, and BIOS.

Bank of America Private Bank offers innovative and customized financial solutions to help meet unique lifestyle, family, business and philanthropic goals for wealthy individuals, families and institutions with complex wealth management needs. A coordinated team backed by more than 200 years of experience and the resources of one of the world’s largest financial institutions works with each client to understand and address their needs. We apply deep wealth management expertise and financial acumen to deliver across a comprehensive range of capabilities, including wealth structuring, investment management, customized credit and banking, legacy and philanthropy, and family office services.

To learn more, please visit: bankofamerica.com/PrivateBank

Vincent Thompson is a Senior Vice President at Bank of America Private Bank. His broad experience spans senior business development roles in the hedge fund and alternative investments business. Leading a team of dedicated specialists, he addresses the financial needs of senior-level corporate executives, business owners, real estate investors, hedge fund and private equity professionals, and generations of wealthy families. Prior to joining The Private Bank, Vincent was Director of Marketing at JPMorgan Incubator Strategies, a venture capital fund focused on seeding hedge funds, a Senior Relationship Manager for Brevan Howard, a large global macro hedge fund, and a Managing Director at Crito Capital, a private placement firm. Vincent holds a BA from the University of Vermont and an MBA in finance from Columbia Business School, where he was a Robert Toigo Fellow.  He also is a CFA® charterholder.

Saghmos Therapeutics is a privately held pharmaceutical company whose mission is to develop innovative therapies for life-threatening cardiovascular and renal diseases with unmet medical needs. Saghmos’ product, ST-62516 (trimetazidine), is poised to enter a Phase 3 study to reduce the risk of Major Adverse Cardiac and Kidney Events (MACKE) after percutaneous coronary intervention (PCI) procedures in patients with unstable angina.

Cardiac and kidney complications after PCI represent an area of significant unmet medical need. There are no approved pharmacological agents to prevent or treat MACKE. Trimetazidine has been approved outside the US for several decades for the treatment of stable angina and ischemic heart failure. In addition, many studies show it reduces kidney injury in patients undergoing PCI. With one million PCI procedures annually in the US, there is a multi-billion dollar opportunity for ST-62516.

Saghmos is seeking funding for the Phase 3 MACKE study, as well as partnering opportunities for ST-62516.